Bridgewater, New Jersey, July 1, 2014 – Valeant Pharmaceuticals International, Inc. and its wholly owned subsidiary, OraPharma, Inc., a specialty pharmaceutical company focused on oral health, have announced the acquisition of Onpharma, Inc., a pioneer in dental anesthetics. Onpharma’s Onset® provides precision buffering of local anesthesia chairside, which allows dentists to administer the drug and perform procedures without ever leaving the patient.
This acquisition enables OraPhama’s strong network of local representatives to make Onset® available and provide support to dental professionals throughout the country, giving dentists and their patients expanded access to this leading anesthetic technology.
“We are thrilled to announce this acquisition as a testament to our continued commitment in advancing oral health care and in offering professionals a comprehensive line of advanced dental care products,” said Steve Sembler, President of OraPharma. “We feel strongly that Onpharma’s Onset® anesthesia technology is a leap forward in both practice efficiency and patient care.”
Along with OraPharma’s existing product offerings, including ARESTIN®, this purchase further positions the organization as the premier dental specialty company with a central focus on both the oral health professionals and patients.
Matt Stepovich, President and CEO of Onpharma said, “We’re excited that becoming part of OraPharma will help us continue our mission to transform dentistry. Our team is dedicated to a seamless transition and current customers can continue to contact us by calling 877-33-ONSET with any questions.”